Novavax logo

Novavax

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

7

Funding Rounds

$2.4b

Money raised

Overview

Clinical stage biotechnology company focused on treating infectious diseases using recombinant nanoparticle vaccine technology

Funding

Funding series

Funding Series Analysis

The company Novavax has raised a total of $2.38b in funding over 7 rounds.

Key Insights:

  • Novavax Grant (money), July 2020: $1.6b
  • Novavax Private equity, June 2020: $200m
  • Novavax Grant (money), May 2020: $384m
  • Novavax Grant (money), March 2020: $4m
  • Novavax Grant (money), September 2015: $89m
  • Novavax Private equity, September 2013: $94.6m
  • Novavax Venture round, June 2008: $5m
Novavax logo
Novavax Grant (money), July 2020 $1.6b
Novavax logo
Novavax Private equity, June 2020 $200m
Novavax logo
Novavax Grant (money), May 2020 $384m
Novavax logo
Novavax Grant (money), March 2020 $4m
Novavax logo
Novavax Grant (money), September 2015 $89m
Novavax logo
Novavax Private equity, September 2013 $94.6m
Novavax logo
Novavax Venture round, June 2008 $5m

Industries

Novavax is active in the following industries:
  • Pharmaceutical industry
  • Vaccine
  • Healthcare
  • Research and development
  • Drug discovery
  • Biomedical engineering
  • Virology
  • Engineering
  • Technology
  • Biology
  • Biotechnology
  • Internal medicine
  • Medicine